BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer?s Disease

BioVie Inc., announced positive analysis of unblinded, topline efficacy data from its Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer?s Disease . Data from evaluable...

Related Keywords

,Biovie Inc ,Drug Administration ,Office Of Scientific Investigations ,Skin Blood ,Good Clinical Practice ,Scientific Investigations ,Modified Intent ,Clinical Dementia Rating Sum ,Neurofilament Light Chain ,Markets ,